Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data
Version of Record online: 5 JUL 2014
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Volume 35, Issue 3, pages 860–869, March 2015
How to Cite
Liver Int. 2015; 35: 860–869
- Issue online: 11 FEB 2015
- Version of Record online: 5 JUL 2014
- Accepted manuscript online: 6 JUN 2014 05:20AM EST
- Manuscript Accepted: 24 MAY 2014
- Manuscript Received: 2 DEC 2013
- Ministry of Health and Welfare. Grant Number: HI10C2020
- Yuhan corp
|liv12605-sup-0001-FigS1A.tif||image/tif||117K||Fig. S1. Antiviral responses during 24 months of therapy in cirrhotic patients without hepatocellular carcinoma.|
|liv12605-sup-0002-FigS2.pptx||application/mspowerpoint||73K||Fig. S2. Levels of total bilirubin, albumin, INR, CTP score and MELD score at baseline, 12 months and 24 months after TBV and ETV therapy in cirrhotic patients without hepatocellular carcinoma (Data are presented as mean ± standard deviation).|
Table S1. Serologic and biochemical response during 24 months of treatment with telbivudine and entecavir in cirrhosis patients without hepatocellular carcinoma.
Table S2. Comparison of changes in hepatic function after 24 months of treatment with telbivudine and entecavir in cirrhosis patents without hepatocellular carcinoma.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.